Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANXA2 | P07355 | 1/20 | 0.47 |
| ▸ | S100A10 | P60903 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 15/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | CCR1 | P32246 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933312 | 1.00 | ANXA2 (0.47) | ANXA2S100A10RXFP1KMT2ACCR1 | |
| SCHEMBL6116273 | 0.97 | RXFP1 (0.44) | ANXA2S100A10RXFP1KMT2ACCR1 | |
| SCHEMBL6116224 | 0.94 | ANXA2 (0.41) | ANXA2S100A10RXFP1KMT2ACCR1 | |
| SCHEMBL6115555 | 0.94 | RXFP1 (0.49) | ANXA2S100A10RXFP1KMT2ACCR1 | |
| SCHEMBL933731 | 0.94 | RXFP1 (0.49) | ANXA2S100A10RXFP1KMT2ACCR1 | |
| SCHEMBL6116048 | 0.93 | RXFP1 (0.43) | ANXA2S100A10RXFP1KMT2AMEN1 | |
| SCHEMBL932796 | 0.92 | PPARG (0.43) | ANXA2S100A10RXFP1KMT2AMEN1 | |
| SCHEMBL932937 | 0.92 | RXFP1 (0.43) | ANXA2S100A10RXFP1KMT2ACCR1 | |
| SCHEMBL8777710 | 0.92 | PPARG (0.43) | ANXA2S100A10RXFP1KMT2AMEN1 | |
| SCHEMBL8777697 | 0.92 | PPARG (0.43) | ANXA2S100A10RXFP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2451800-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | Vivalis (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | NAT1, POLM, PYGL | ANXA2 4355/4885S100A10 1052/4885RXFP1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.